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In this study, we tried a DNA vaccination regime in rhesus macaques using a full genome HIV-1 plasmid. The HIV-1 genome
is under the control of its original LTR promoter, but has a mutated zinc finger motif gene in the nucleocapsid region. Due
to the lack of genomic RNA packaging, the plasmid produces only noninfectious viral particles. We repeatedly injected four
macaque monkeys intramuscularly with the naked DNA over a period of 40 weeks. To evaluate the humoral and cell-mediated
immunity provided by this DNA vaccination, no other booster or other recombinant viral vectors were used. Immunological
responses against HIV-1 were elicited in all of the vaccinated monkeys: stable anti-HIV-1 Env antibodies were raised in two
monkeys and CTL activities were induced in the other monkeys. The macaques were intravenously challenged at 54 weeks
with 100 TCID50 of SHIV-NM-3rN, which possesses an envelope gene homologous to the one in the vaccinated plasmid. In
all of the vaccinated macaques, the peak plasma viral loads induced by the challenge virus were two to three orders of
magnitude lower than those of the naive controls. These results suggest that a DNA vaccination regime with a full genome














Acquired immunodeficiency syndrome (AIDS) has
taken a total of 16 million lives (World Health Organiza-
tion, 1999). Despite recent therapeutical advancements
such as highly active antiretroviral treatment therapy,
nearly 6 million people were newly infected with human
immunodeficiency virus type 1 (HIV-1) in 1999. The ma-
jority of those having the virus are unable to receive
advanced therapies because of problems purchasing
expensive drugs. Therefore, there is a clear need for a
preventive vaccine against AIDS.
Although an AIDS vaccine for practical human use has
not yet been produced, live attenuated vaccines have
been shown to be the most effective in nonhuman pri-
mate models. In simian immunodeficiency virus (SIV) or
simian human immunodeficiency virus (SHIV)/macaque
models, SIV or SHIV vaccines attenuated by way of gene
modifications have protected monkeys from homologous
and heterologous challenge viruses (Clements et al.,
1995; Daniel et al., 1992; Hayami et al., 1999; Igarashi et
l., 1997; Shibata et al., 1997; Ui et al., 1999). An advan-
age of using live attenuated vaccines is that they mimic
atural infection in the host. However, the safety of at-g
t
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116enuated vaccines for human use is questionable be-
ause they have been shown to be pathogenic in neo-
ates and possibly even in adult monkeys (Baba et al.,
995; Baba et al., 1999).
Another candidate for AIDS vaccine development is
DNA vaccination, which can elicit both humoral and
cell-mediated immunity. This method consists of the in-
jection of DNA plasmids which encode antigenic pro-
teins under a strong enhancer/promoter such as the
human cytomegalovirus (CMV) immediate/early pro-
moter, the Rous sarcoma virus LTR, or the SV40 early
promoter. Applying the DNA vaccination regime to AIDS
vaccine development is safe and appears to be promis-
ing. In the HIV-1 chimpanzee model, Boyer et al. (1997)
reported protection against HIV-1. In SHIV/macaque
models, Letvin et al. (1997) reported protection against
HIV, and Robinson et al. (1999) reported protection
gainst homologous and heterologous SHIVs. Nonethe-
ess, these three reports employed DNA vaccination in
ombination with a boosting of antigenic proteins or live
iral vectors. So far, none of the vaccination regimes
sing DNA alone has yet achieved complete protection,
hich is in contrast to the rather satisfactory results
btained with live attenuated vaccines.
In this study, we investigated a DNA vaccination re-
ime using a full genome plasmid expressing noninfec-

































117DNA VACCINATION BY A FULL GENOME HIV-1 PLASMIDpromoter, HIV-1 LTR. The plasmid termed pNL432-ZF1*
was originally produced by our research group (Mizumo
et al., 1996) and it has mutations (Cys . . . Cys . . . His
. . . Cys to Ser . . . Ser . . . His . . . Cys) in an N-terminal zinc
finger motif of the nucleocapsid protein (Fig. 1). This
motif is believed to play an important role in packaging
the viral genomic RNA. The mutant plasmid expresses
whole virus particles that do not possess the genomic
RNA. An advantage of this plasmid is that it is capable of
expressing all of the viral antigenic components includ-
ing Gag and Pol proteins. Although there is a difficulty in
overcoming the question of antigenic variability in the
case of Env-expressing vaccination regimes, Gag and
Pol proteins are known to be cross-reactive among the
primate lentiviruses and therefore an additional protec-
tion effect can be anticipated. Besides, the present re-
gime more closely resembles the use of a live attenuated
vaccine than the foregoing DNA vaccination regimes.
Live attenuated vaccines replicate in the infected cells
and viral antigenic components are presented by way of
MHC on the infected cell surface, which elicits a strong
immunity against the virus in the host. Viral genes con-
tained in the full genome plasmid are expected to be
expressed in a similar manner, leading to assembly of
viral components and budding of viral particles in the
cells that took up the plasmid. This series of events is
believed to be effective for acquisition of cellular and
humoral immunity in the host.
In the present study, we vaccinated four macaques
with the plasmid. Two of them acquired antibodies, and
two of them acquired cytotoxic T lymphocytes (CTL)
against HIV-1. All of the monkeys showed partial protec-
tion against the challenge of an HIV-1/SIVmac chimeric
virus (SHIV) strain, termed NM-3rN (Kuwata et al., 1995),
hat possesses an envelope gene homologous to the
ne in the vaccinated plasmid. Namely, the RNA loads of
he challenge virus (copy numbers per milliliter) were
FIG. 1. HIV-1 zinc finger motifs in nucleocapsid and HIV-1 ZF1*
mutations in zinc finger sequences. Mutated amino acids residues are
underlined.wo to three orders of magnitude lower than they were in
he naive controls. To our knowledge, this is the firsteport of the efficacy of DNA vaccination alone with a
iral full genome regime in monkeys.
RESULTS
ntibody responses in DNA-vaccinated macaques
Four macaques (MM143, MM145, MM146, and
M153) were vaccinated using a DNA vaccination re-
ime with an HIV-1 full genome plasmid pNL432-ZF1*.
he vaccination schedule and the antibody responses of
he vaccinated monkeys to HIV-1 Env measured by
LISA are shown in Fig. 2. The monkeys were injected
ntramuscularly (i.m.) with 500 mg DNA per injection for a
otal of 14 times. Initially the monkeys were vaccinated at
and 2 weeks post initial vaccination (wpv). However, up
ntil 15 wpv, none of the monkeys showed an antibody
esponse against Env. Then we injected the plasmid in
wo sets of DNA immunization series. Each set was
omposed of one injection per week for 4 consecutive
eeks. We injected at 16–19 wpv, and after an interval of
weeks we gave the second set of DNA immunizations
t 22–25 wpv. Two of the four vaccinated monkeys
MM143 and MM146) began to raise antibodies against
IV-1 Env during the second set of DNA immunizations
t the 8th DNA injection (at 25 wpv). At 35–38 wpv we
njected all of the monkeys with the third set of DNA
mmunizations to achieve higher antibody titers in the
wo monkeys (MM143 and MM146) and to stimulate
ntibody response in the other monkeys (MM145 and
M153). The third set of DNA immunizations worked as
booster for MM143 and MM146 and antibody titers
FIG. 2. Antibody responses against HIV-1 Env in monkeys immunized
with pNL432-ZF1* measured by an ELISA assay (Generavia Mixt, Fu-
jirebio, Inc., Tokyo, Japan). The arrows indicate the times of DNA















118 AKAHATA ET AL.reached their highest values at the 14th injection (at 38
wpv). In the other two monkeys (MM145 and MM153) no
detectable anti-Env antibodies were observed up until
the challenge day.
Antibody titers against HIV-1 were also measured by
particle-agglutination (PA) measurement, which gave re-
sults that were almost the same as those obtained by
ELISA. Antibodies against HIV-1 were detected in
MM143 and MM146 but not in MM145 or MM153. None-
theless, the PA measurement was less sensitive than the
ELISA measurement. In fact, no antibody against HIV-1
was detected in MM143 until the 13th injection (at 37
wpv); after the 14th injection (at 38 wpv) the antibody
turned out to be faintly positive (judged as plus or minus
according to the manufacturer’s manual). In MM146, the
antibody titers against HIV-1 changed to faintly positive
(plus or minus) after the 10th injection (at 25 wpv), to 32
at the 12th injection (at 36 wpv), and to 2048 after the 13th
injection (at 37 wpv). No antibodies were detected in
MM145 or MM153.
As shown by an immunoblotting assay, sera of MM146
at 38, 41, and 54 wpv contained antibodies against p24
and gp160. Sera of MM143 at 38 and 41 wpv did not
show any specific antibody but sera at 54 wpv showed
antibodies against p24. No specific antibodies against
HIV-1 were detected in MM145 or MM153 at 38, 41, and
54 wpv (data not shown).
Although we measured neutralizing antibodies of all of
the vaccinated monkey sera of 24, 37, 40, and 54 wpv, we
TABLE 1





% Killer cell activities
(E:T; 100:1)
Antibody against
HIV-1 EnvHIV-1 Env HIV-1 Gag
MM143 0.0 0.0 1
MM145 29 9.0 8.9 2
MM146 (10 toi)a 2.1 0.0 1
MM153 0.0 7.6 2
MM143 2.1 0.0 1
MM145 32 12.9 0.0 2
MM146 (10 toi) 0.0 0.0 1
MM153 14.6 6.6 2
MM143 0.0 0.0 1
MM145 42 6.1 11.2 2
MM146 (14 toi) 0.0 2.1 1
MM153 0.0 0.0 2
MM143 0.0 0.0 1
MM145 53 0.0 3.8 2
MM146 (14 toi) 0.0 0.0 1
MM153 13.1 0.0 2a Times of DNA injections.did not detect any neutralizing antibody for HIV-1 NL432
(Table 3).
HIV-1 Env- and Gag-specific killer cell activities
Table 1 summarizes HIV-1 Env- and Gag-specific killer
cell activities in the vaccinated monkeys at four times
between 29 and 53 wpv. MM145 showed HIV-1 Env- and
Gag-specific killer cell activities (against Env at 29 and
32 wpv and against Gag at 29 and 42 wpv). MM153 also
showed HIV-1 Env- and Gag-specific killer cell activities
(against Env were at 32 and 53 wpv and against Gag at
29 wpv). MM143 and MM146 did not show any HIV-1
Env- or Gag-specific killer cell throughout this vaccina-
tion period. These activities were lower than those in-
duced by live attenuated vaccines of gene-defective or
gene-deleted SHIVs (Igarashi et al., 1997; Ui et al., 1999).
IFN-g production by T cell lymphocytes
PBMCs obtained from the vaccinated monkeys at 54
pv and from naive controls were cultured in the pres-
nce of HIV-1 rgp160. PBMCs of all of the vaccinated
onkeys secreted IFN-g, indicating the presence of an-
igen-specific helper T cell lymphocyte memory re-
ponses, while those of the naive controls showed no
easurable production (Table 2). It is noteworthy that
FN-g production in MM145, in which HIV-1 Env- and
ag-specific killer cell activities were evidently induced,
as about five times higher than the levels in the other
hree vaccinated monkeys.
lasma viral loads of the challenge virus
The vaccinated monkeys were intravenously chal-
enged with a 100 TCID50 dose of SHIV-NM-3rN at 54 wpv
(16 weeks after the previous (14th) injection). Two naive
macaques, MM125 and MM126, were also inoculated as
unvaccinated controls.
Plasma viral loads were monitored by quantitative
RT-PCR (Fig. 3). Viral RNA was not detected in all the
TABLE 2








Note. Cell culture supernatant from 1 3 106 cells/ml PBMC in the
resence of 1.33 mg/ml rgp160 for 72 h were measured by ELISA
(Toyobo, Japan).macaque sera before the challenge with infectious virus.















119DNA VACCINATION BY A FULL GENOME HIV-1 PLASMIDwere approximately 2 3 103 (MM126) and 2 3 104
(MM125) copies/ml. Then at 2 wpc, the viral loads of
these two monkeys reached their peak values (both
approximately 107 copies/ml). On the other hand, the viral
oads of all the vaccinated monkeys at 1 wpc were below
3 103 copies/ml. At 2 wpc, the viral load of MM146 was
below the detectable level. At 2 wpc, the viral loads of
three of the vaccinated monkeys (MM143, MM145, and
MM153) were two to three orders of magnitude lower
than those of the naives. The peak viral loads of the
vaccinated monkeys were also two to three orders of
magnitude lower than those of the naives. Among the
vaccinated monkeys, MM146, which had the highest
titers of antibody against HIV-1 before the challenge,
showed the lowest viral load. Interestingly, the peak of
viral loads of the two monkeys that had antibodies
against HIV-1 (MM143 and MM146) was delayed, occur-
ring at 3 wpc, while those of the other monkeys (naives
and MM145 and MM153) occurred at 2 wpc. Further-
more, the viral loads of MM145 and MM153, which had
HIV-1 Env- or Gag-specific killer activities, decreased
near or below the detectable level after 4 wpc, while the
viral loads of MM146 and MM143, which had antibodies
against HIV-1, were detectable until 6 and 8 wpc, respec-
tively.
Provirus detection in PBMCs after the challenge
Proviral copy numbers in the PBMCs of the vaccinated
monkeys and the naives were determined after the chal-
lenge inoculation (Fig. 4). In the two naive controls, pro-
virus was detected at 2 wpc and reached a peak at 4
wpc, and the copy numbers remained at the peak level
until 6 wpc. On the other hand, the proviral copy numbers
of three of the vaccinated monkeys (MM145, MM146, and
MM153) were one to two orders of magnitude lower than
FIG. 3. Plasma viral loads of vaccinated and the naive control
macaques after challenge with SHIV NM-3rN. Plasma viral loads were
measured by RT-PCR.those of the naive control monkeys. At 6 wpc, the copy
numbers of these three monkeys decreased. In contrastto the proviral copy numbers of these three vaccinees,
the proviral copy numbers of MM143 were similar to or
slightly less than those of the naive controls till 6 wpc. No
proviral DNA was detected in any of PBMCs of the
vaccinated macaques before this challenge.
DISCUSSION
None of the four vaccinated monkeys attained com-
plete protection. However, the plasma viral RNA load
after the challenge, which is an index of the viral activity
in the blood, ranged from 103 to 105 copies/ml in all four
monkeys. Importantly, these values were two to three
orders of magnitude lower than those of the controls. In
recent studies, early plasma viral RNA load has been
considered a predictor of disease development and mor-
tality in both human and macaque models (Hirsch et al.,
1996; Lefrere et al., 1998; Lifson et al., 1997; Mellors et al.,
1996; Staprans et al., 1999). In previous macaque models
of vaccines or early drug treatment regimes, setting the
pathogenic SIV viral load at two or greater orders of
magnitude lower than those of the untreated naive con-
trols in the early state of the infection prevented devel-
opment of disease (Davis et al., 2000; Lifson et al., 1997;
Nowak et al., 1997; van Rompay et al., 1999). In the
resent study, we used a nonpathogenic virus (SHIV
M-3rN) as a challenge virus, so we were unable to
etermine whether our DNA vaccination regime prevents
isease development. However, it seems that a de-
rease in plasma viral loads two to three order of mag-
itude in the early state of the infection would be impor-
ant in preventing the development of disease.
The immune responses of the four monkeys observed
n this DNA vaccination seemed to be classified into two
ypes. MM143 and MM146 showed antibody responses
gainst Env and Gag but did not show CTL against Env
r Gag. On the other hand, MM145 and MM153 showed
TL against Env and Gag but did not show any antibody
FIG. 4. Proviral copy numbers in PBMCs of the vaccinated and naive
control macaques after challenge with SHIV NM-3rN. Copy numbers




























120 AKAHATA ET AL.response against Env or Gag. We tentatively call the
former monkeys the antibody-induced monkeys and the
latter monkeys the CTL-induced monkeys. We suggest
that the reduction of viral loads in these two types of
monkeys is mediated by different mechanisms for the
following reasons.
The CTL-induced monkeys (MM145 and MM153)
showed low CTL responses against HIV-1 Env or Gag.
However, even in monkeys that had conventional DNA
vaccinations, lysis of more than 10% of specific target
cells by CTL was difficult to achieve (Boyer et al., 1997;
Putkonen et al., 1998). Robinson et al. (1999) reported
that monkeys vaccinated by DNA priming followed by a
recombinant fowlpox virus boosting regime were pro-
tected although their CTL levels were close to back-
ground levels and suggested that their protective re-
sponse might have been mediated by a nonlytic T-cell
activity. Interestingly, in our study, the decrease of the
viral loads was more evident in the CTL-induced mon-
keys than in the antibody-induced monkeys. The de-
crease was so drastic that the viral loads of the CTL-
induced monkeys were near or below the detectable
level after 4 wpc. On the other hand, the viral loads of the
antibody-induced monkeys were detectable for a longer
period. We presume that the rapid reduction of the viral
load in the CTL-induced monkeys might be mediated
mainly by cellular immunity.
The antibody-induced monkeys (MM143 and MM146)
showed partial protection against the challenge virus,
although they did not show any neutralizing antibodies
throughout the vaccinated period. We cannot explain
why the viral loads of the challenge virus were reduced
in the absence of neutralizing antibodies. However, the
antibody-induced monkeys exhibited a slight rise of neu-
tralizing antibodies 4 weeks postchallenge (Table 3).
These neutralizing antibodies might be a consequence
of an anamnestic reaction induced by the challenge virus
TABLE 3
Neutralizing Activities of NM-3rN Inoculated Monkeys’ Sequential
Sera against HIV-1 NL432
Monkey Before challenge
Weeks postchallenge
2 4 8 10 12
M143 — — 20 20 a a
MM145 — — — — a a
MM146 — — 20 20 a a
MM153 — — — — a a
MM125b — — — — — —
M126b — — — — 20 20
a All of the vaccinated monkeys were sacrificed at 8 weeks postchal-
enge.
b These monkeys are unvaccinated controls.rather than a consequence of infection. In fact, the other
vaccinated monkeys did not show any neutralizing anti-bodies at least until the time of sacrifice (8 wpc) and in
the unvaccinated controls neutralizing antibodies started
10 wpc or later. It is unclear whether the partial protec-
tion was due to barely detectable neutralizing antibodies
or some other mechanism such as an antibody-depen-
dent cell cytotoxicity (ADCC). An HIV-1 Env-specific
helper T cell response revealed by secretion of IFN-g
(Table 2) might also be involved in reducing viral loads.
In this study, the two vaccinated monkeys showed only
a CTL response, and the other monkeys showed only an
antibody response. It is intriguing that the monkeys
showed different patterns of immune response after re-
ceiving the same injection protocol. In previous experi-
ments, most nonhuman primates and chimpanzees vac-
cinated with DNA alone showed both antibody and CTL
or occasionally only an antibody response (Boyer et al.,
997; Lu et al., 1996; Robinson et al., 1999; Haigwood et
l., 1999). It is said that overexposure to the antigens may
ave shifted the immunity from Th1 type to Th2 type
Fuller and Haynes, 1994; Haynes et al., 1994). The im-
munity of the antibody-induced monkeys may have
shifted from Th1 type to Th2 type, while that of the
CTL-induced monkeys may have remained Th1 type.
Contrastingly, as a case of CTL-only responses, Hosie et
al. (1998) described a DNA vaccination regime for cats
using a replication-defective FIV full genome plasmid
under the virus’s original LTR. In their study, cats were
injected three times with 100 mg of the replication-defec-
ive FIV full genome DNA. The vaccinated cats showed a
TL response but did not show any antibody response.
NA vaccination with a full genome plasmid under the
riginal promoter LTR might tend to induce only cell-
ediated immunity during the period soon after the vac-
inations, whereas DNA vaccination using the conven-
ional mammalian promoter might tend to induce both
umoral and cell-mediated immunity or only humoral
mmunity due to the abundant antigen expression of the
trong promoter.
It would be instructive to compare our DNA vaccina-
ion regime with other DNA vaccination regimes with
espect to the amount of DNA injected. Previous DNA
accination trials with human, chimpanzee, or nonhuman
rimates have usually adopted antigen-expressing plas-
ids under mammalian promoters such as CMV. For
xample, HIV-1-infected humans injected three times
ith 100 mg of nef, rev, or tat cDNA under the CMV
romoter showed increases in HIV-1-specific cytoxicity
Calarota et al., 1998). Boyer et al. (1997) injected three
himpanzees six times with 100 mg of gp160-expressing
plasmid, three times with 100 mg of gag/pol-expressing
plasmid, and two times with 1 mg of purified gp160 and
gag/pol proteins as a boost. Two of the chimpanzees
showed antibody against Env and CTL against Env or
Gag. The third chimpanzee showed an antibody re-
sponse against Env, but did not show any CTL against



















121DNA VACCINATION BY A FULL GENOME HIV-1 PLASMIDmacaques by an intradermal route three times with 500
mg of five different plasmids, which expressed the gag,
pol, env, and nef genes of SHIV-IIIb, totaling 2.5 mg
DNA/injection. All of the monkeys showed Env antibody,
and 4 of them showed weak CTL (5–20%) against Gag,
Env, or Nef. Letvin et al. (1997) injected 2 monkeys five
times with 1–2 mg of gp120-expressing plasmid mixed
with 100 mg of o-gp160IIIB and four times with 1 mg of
gp160-expressing plasmid. The injected monkeys
showed abundant antibodies and CTL (10–40%) against
Env or Gag. In our study, the four rhesus macaques were
injected 14 times with 500 mg of the full genome HIV-1
plasmid. Two monkeys (MM143 and MM146) showed an
antibody response against Env after the 8th injection and
the other two monkeys (MM145 and MM153) showed
HIV-1 Env- and Gag-specific killer cell activities (8–20%)
after the 10th injection. Compared with the total amount
of injected DNA in the foregoing rhesus macaque exper-
iments, the amount of DNA in our regime was not much,
yet we achieved an approximately equal efficiency in
inducing an immune response. However, compared with
the humans and chimpanzees injected with DNA under
the CMV, our monkeys required much more time to
acquire the antibody or CTL response. Thus, to make this
DNA vaccination practically feasible, the frequency
(number of times) of injection needs to be decreased.
There might be some reluctance to use full genome
plasmids as vaccines because of the possibility of rever-
sion to the pathogenic wild type. In our previous study
(Mizuno et al., 1996), we confirmed the replication defec-
tiveness of the used plasmid pNL432-ZF1* in an in vitro
analysis. When M8166 cells (a human T cell line) were
transfected with the plasmid, none of the live virus due to
a reversion mutation was observed during an observa-
tion period for over 30 days. When we designed the
plasmid pNL432-ZF1*, we introduced mutagenesis of a
total of four nucleotides to alter two cysteines to two
serines in the N-terminal zinc finger motif to minimize the
possibility of reversion. Thus the reversion to the wild
type seems to be very unlikely. To further confirm the
safety of our vaccination regime, we used nested PCR to
detect provirus in the PBMCs of vaccinated monkeys
throughout the course of the vaccination. No provirus
was detected. In addition, CD4 numbers in PBMCs were
in the normal range throughout the course of the exper-
iment (data not shown).
A common strategy for increasing protection was to
combine DNA vaccinations with protein boosting as
seen in other studies. In the present study, however, we
did not use any boosting regimes because our objective
was to clarify the effectiveness of DNA vaccination using
a full genome plasmid. As mentioned above, this DNA
vaccination regime was proved to be potentially effec-
tive. Future research will focus on how to modify this
regime for achieving better protection.
m
tMATERIALS AND METHODS
Plasmid for DNA vaccination
The HIV-1-bearing plasmid used for DNA vaccination
in this study was pNL432-ZF1* (Mizuno et al., 1996). In
brief, this plasmid is derived from pNL432, an infectious
molecular clone of HIV-1 (Adachi et al., 1986), in which
the first two cysteine residues of the N-terminal zinc
finger motif (Cys-X2-Cys-X4-His-X4-Cys) were replaced
by serine residues (Fig. 1). The zinc finger motif is be-
lieved to be important for packaging of the virus genomic
RNA. Mizuno et al. (1996) showed that this mutated
plasmid expressed whole HIV-1 virions similar to the
wild-type HIV-1 virions by electron microscopy examina-
tion but these virions were noninfectious because they
lacked the genomic RNA.
Vaccination protocol
Four mature male rhesus macaques (Macaca mulatta)
(MM143, MM145, MM146, and MM153) were vaccinated
by i.m. injection with pNL432-ZF1*. The plasmid was
multiplied in Escherichia coli on a large scale and ex-
tracted from the cells by the conventional alkali lysis
method followed by purification with ethanol and poly-
ethylene glycol precipitation. The macaques were in-
jected at two points on the right quadriceps and at two
points on the calves with a solution containing 500 mg
pNL432-ZF1* in 450 ml PBS and 450 ml bupivacaine
Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan) per
njection.
nimals
All of the macaques were serologically negative for
IV and simian T-cell lymphotropic virus type 1 before
he vaccination. They were housed throughout the ex-
erimental period and autopsies were carried out in
ccordance with regulations approved by the Institu-
ional Animal Care and Use Committee of the Institute for
irus Research, Kyoto University.
ssays for antibodies
The titers of anti-Env antibodies in the plasma of the
accinated monkeys were determined by a Genelavia
ixt kit (Fujirebio, Inc., Tokyo, Japan) (Simon et al., 1994)
ollowing the manufacturer’s recommendations. The kit
s based on the sandwich enzyme-linked immunosorbent
ssay, and the antigens were coated with the recombi-
ant protein HIV-1 gp160 and synthetic peptides HIV-1
p41 and HIV-2 gp36 in the microtiter plates.
Particle agglutination was measured by a Serodia HIV
it (Serodia HIV, Fujirebio), and immunoblotting was












122 AKAHATA ET AL.Assay for neutralizing antibodies
Heat-inactivated sera of all the vaccinated monkeys
and naive controls were diluted 20-fold with RPMI 1640
medium supplemented with 10% heat-inactivated fetal
bovine serum (Gibco-BRL) and 20 mM L-glutamine. Di-
uted serum samples (200 ml) were mixed with an equal
olume of HIV-1 NL432 virus (100 TCID50 per 50 ml), and
he mixture was incubated at 37°C for 90 min. Aliquots of
he virus–serum mixtures (100 ml) were then cocultured
with 2 3 104 M8166 cells (a human CD41 lymphoid cell
line) in triplicate. After 4–9 days, RT activities of the
supernatants were measured; a reduction in RT activity
of at least 50% was considered indicative of virus neu-
tralization.
Assay for HIV-1 Env- and Gag-specific killer cell
activities
Specific killer cell activities for HIV-1 Env and HIV-1
Gag were measured by the modified method of
Yamamoto et al. (1990). Herpesvirus papio-transformed B
lymphocyte cell lines (B-LCL) established from the re-
spective monkey peripheral blood mononuclear cells
were infected with an HIV-1 Env- (HIV-1 IIIb) or HIV-1 Gag
(HIV-1 IIIb)-expressing recombinant vaccinia virus and
used as target cells. The parental vaccinia-virus-infected
and noninfected cells were used as the control targets.
Env- and Gag-specific killer cell activities were ex-
pressed as the percentage of specific lysis, (% specific
lysis) 5 (% lysis of the HIV-1 Env- or Gag-expressing
B-LCL) 2 (% lysis of the parental vaccinia-virus-infected
B-LCL), when the effector:target cell ratio was 100:1. In
the fresh PBMC method, autologous and heterologous
PBMCs were directly used for the effector cells. In the
antigen stimulation method, the respective monkey B-
LCL were infected with HIV-1 Env- or Gag-expressing
vaccinia virus, killed by treatment with glutaraldehyde,
and used as antigen-stimulator cells. The respective
monkey PBMCs were stimulated by HIV-1 Env- or Gag-
expressing B-LCLs, and incubated for 5 days. The stim-
ulated PBMCs were used as the effector cells. At 29, 32,
and 42 wpv, HIV-1 Env- and Gag-specific killer cell ac-
tivities were measured using the fresh PBMC method. At
53 wpv, the assays were measured by the antigen stim-
ulation method.
Assay for IFN-g
PBMCs (1 3 106 cells/ml) obtained from the vacci-
ated monkeys at 54 wpv and naive controls were cul-
ured in the presence of 1.33 mg/ml HIV-1 rgp160 (HIV-1
IIIB gp160 Recombinant Viral Protein, Advanced Biotech-
nologies, Inc.) for 72 h. Then the culture supernatants
were harvested, and secreted IFN-g was measured by
an ELISA kit (Toyobo, Japan) following the manufacturer’s
recommendations.Challenging virus
We used a simian human chimeric virus termed NM-
3rN as a challenging virus, in which env, rev, tat, vpu, and
vpr genes are derived from HIV-1 strain NL432 and the
rest of the genome is from SIVmac239 (Kuwata et al.,
1995). The SHIV-NM-3rN was grown on macaque mon-
key PBMCs, and cell-free virus stock was prepared. Four
vaccinated macaques and two naive macaques were
challenged with 1 3 102 TCID50 of SHIV-NM-3rN intrave-
nously.
Detection of plasma viral RNA
Plasma viral loads were determined after the chal-
lenge. Viral RNAs were extracted from the plasma by a
viral RNA kit (Qiagen), and their levels were determined
by quantitative RT-PCR using a Taqman RT-PCR kit (Per-
kin–Elmer) (Suryanarayana et al., 1998). Primers used in
this assay were SIVII-696F (59-GGAAATTACCCAGTA-
CAACAAATAGG-39) and SIVII-784R (59-TCTATCAATTT-
TACCCAGGCATTTA-39), and the probe was SIVII-731 (59-
Fam-TGTCCACCTGCCATTAAGCCCG-Tamra-39) (Perkin–
Elmer). For a standard curve, quantitative assays for the
measurement of viral RNA copy numbers in plasmas of a
SHIV-infected monkey were performed by Bayer Refer-
ence Testing Laboratory (Emeryville, CA) with a
branched DNA signal amplification assay (Pachl et al.,
1995; Tsai et al., 1997). For each run, a standard curve
was generated from dilutions of viral RNA extracted from
the monkey’s plasma. Under these conditions, the detec-
tion limit was 250 copies/ml.
Provirus detection in PBMCs
Proviral copy numbers in the monkey PBMCs were
also determined by a Taqman RT-PCR kit (Perkin–Elmer).
Primers and probes were the same ones used for mea-
suring plasma viral loads. The PBMCs of the vaccinated
macaques were prepared by Percoll density gradient
centrifugation (Pharmacia). PBMCs (1 3 106) were dis-
olved in a proteinase K buffer at 56°C for 2 h. The
roviral copy numbers in 1 3 106 PBMCs were measured
with a quantitative PCR kit (Taqman, Perkin–Elmer). A
mixture of concentration-known pMA239 (calculated
from the OD260 value) and PBMCs from a normal monkey
ere used for a standard curve. Under these conditions,
he detection limit was 10 copies.
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